Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Advanced Solid Tumors 5Carcinoma, Non-Small-Cell Lung 3Solid Tumors 2Rectal Neoplasms 2Colonic Neoplasms 2Solid Tumor 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1Adenocarcinoma 1

Interventions

Sorafenib 5lenvatinib 2ledipasvir, sofosbuvir drug combination 2halofantrine 2atezolizumab 2Liver Transplantation 2Immunotherapy 2Control Groups 2Blood Specimen Collection 2Bevacizumab 2Antibodies 2veliparib 1trifluridine tipiracil drug combination 1trametinib 1titanium silicide 1sintilimab 1rubitecan 1repotrectinib 1pevonedistat 1pembrolizumab 1ozanimod 1linifanib 1genexol-PM 1fluorocholine 1fisogatinib 1ficlatuzumab 1durvalumab 1camrelizumab 1belinostat 1bavituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Diseases × linifanib × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡